Status:
UNKNOWN
Prognostic Biomarkers of Pancreatic Cancer Based on Proteomic Techniques
Lead Sponsor:
The Affiliated Hospital of Qingdao University
Conditions:
Proteomics
Pancreatic Cancer
Eligibility:
All Genders
Brief Summary
Sequence I (Retrospective study: proteomic analysis of pathological specimens and information collection of previous patients with pancreatic cancer) Sequence 2 (Non-interventional prospective study, ...
Detailed Description
Sequence 1 was a retrospective study, which collected pathological tissue samples (continuous cut white slices, 10 slices per case, 2 of which were HE stained slices) and clinical data (including clin...
Eligibility Criteria
Inclusion
- Sequence 1 (pathological specimens and information collection of pancreatic cancer patients):
- Chinese patients, regardless of age and gender;
- patients with pancreatic cancer confirmed by pathology;
- Patients without a second primary tumor;
- The clinical diagnostic information to be collected within three months before sampling is relatively complete.
- Sequence 2 (samples and information collection of patients with pancreatic cancer):
- Chinese patients, regardless of age and gender;
- Subjects must obtain informed consent and sign informed consent, indicating that they understand the purpose and procedure of this study and are willing to participate in the study;
- Patients with pancreatic malignancy diagnosed by pathology;
- Patients without a second primary tumor.
- Sequence 3 (healthy subject samples and information collection)
- Chinese healthy male or female, aged 18-45;
- Subjects must obtain informed consent and sign informed consent, indicating that they understand the purpose and procedure of this study and are willing to participate in the study;
- Physical examination, vital signs, laboratory examination (blood routine, blood biochemistry and urine routine), 12 lead ECG and other normal or abnormal persons without clinical significance
Exclusion
- Sequence 1 :
- The quality of pathological specimens of patients can not meet the requirements of proteomics;
- The researchers believe that patients who are not suitable for proteomic analysis.
- Sequence 2:
- patients with other malignant tumors (non pancreatic cancer metastasis).
- hepatitis B surface antigen positive, hepatitis C antibody positive, HIV antibody positive or syphilis antibody positive;
- Pregnant or lactating women;
- The researcher believes that it is not suitable to participate in this experiment.
- Sequence 3:
- Abnormalities of clinical significance judged by clinicians, including physical examination, vital signs examination, ECG or clinical laboratory examination results;
- hepatitis B surface antigen positive, hepatitis C antibody positive, HIV antibody positive or syphilis antibody positive;
- Those who have participated in other clinical trials of drugs and accepted clinical trials of drugs or devices for trial within the first three months;
- Those vaccinated with active or attenuated vaccine within 1 month before screening or during the planned trial;
- Pregnant or lactating women;
- Those who have taken any drugs within the first 14 days;
- The researcher believes that it is not suitable to participate in this experiment.
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT05289895
Start Date
April 1 2022
End Date
December 30 2024
Last Update
March 22 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.